NASDAQ:CBPO - China Biologic Products Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$79.12 -1.75 (-2.16 %)
(As of 05/25/2018 06:00 AM ET)
Previous Close$79.12
Today's Range$78.32 - $81.9425
52-Week Range$71.85 - $116.73
Volume326,030 shs
Average Volume222,333 shs
Market Capitalization$2.71 billion
P/E Ratio15.98
Dividend YieldN/A
Beta1.47

About China Biologic Products (NASDAQ:CBPO)

China Biologic Products logoChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111

Debt

Debt-to-Equity RatioN/A
Current Ratio6.51
Quick Ratio4.55

Price-To-Earnings

Trailing P/E Ratio15.98
Forward P/E Ratio16.80
P/E Growth1.33

Sales & Book Value

Annual Sales$370.41 million
Price / Sales7.08
Cash Flow$4.5057 per share
Price / Cash17.56
Book Value$37.18 per share
Price / Book2.13

Profitability

EPS (Most Recent Fiscal Year)$4.95
Net Income$67.94 million
Net Margins17.76%
Return on Equity17.29%
Return on Assets14.89%

Miscellaneous

Employees1,799
Outstanding Shares33,130,000

China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.22 by $0.01. The biopharmaceutical company earned $112.50 million during the quarter, compared to analysts' expectations of $118.25 million. China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. The firm's revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 EPS. View China Biologic Products' Earnings History.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for China Biologic Products.

What price target have analysts set for CBPO?

3 analysts have issued 1-year price targets for China Biologic Products' shares. Their forecasts range from $97.00 to $105.00. On average, they anticipate China Biologic Products' share price to reach $101.00 in the next twelve months. View Analyst Ratings for China Biologic Products.

Who are some of China Biologic Products' key competitors?

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the folowing people:
  • Mr. Xiaoying Gao, Chairman, Pres & CEO (Age 67)
  • Mr. Ming Yang, Chief Financial Officer (Age 46)
  • Mr. Ming Yin, Sr. Corp. VP (Age 40)
  • Ms. Zhijing Liu, Corp. VP (Age 64)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53)

Has China Biologic Products been receiving favorable news coverage?

Press coverage about CBPO stock has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. China Biologic Products earned a media sentiment score of 0.09 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.04%), BlackRock Inc. (2.80%), Hsbc Holdings PLC (2.06%), FIL Ltd (1.06%), Artisan Partners Limited Partnership (0.93%) and Wasatch Advisors Inc. (0.88%). Company insiders that own China Biologic Products stock include David Gao, Ming Yang, Sean Shao, Wenfang Liu, Wp X Biologics Llc and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products.

Which institutional investors are selling China Biologic Products stock?

CBPO stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FIL Ltd, Schroder Investment Management Group, Sei Investments Co., Baillie Gifford & Co., California Public Employees Retirement System, Rudman Errol M and JPMorgan Chase & Co.. View Insider Buying and Selling for China Biologic Products.

Which institutional investors are buying China Biologic Products stock?

CBPO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., BNP Paribas Arbitrage SA, Wasatch Advisors Inc., Jupiter Asset Management Ltd., Hsbc Holdings PLC, UBS Group AG, Comerica Bank and Azimuth Capital Management LLC. View Insider Buying and Selling for China Biologic Products.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $79.12.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $2.71 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,799 workers across the globe.

How can I contact China Biologic Products?

China Biologic Products' mailing address is JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD 18TH FLOOR, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]


MarketBeat Community Rating for China Biologic Products (CBPO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

China Biologic Products (NASDAQ:CBPO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for China Biologic Products in the last 12 months. Their average twelve-month price target is $101.00, suggesting that the stock has a possible upside of 27.65%. The high price target for CBPO is $105.00 and the low price target for CBPO is $97.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.332.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $101.00$101.00$137.50$137.50
Price Target Upside: 27.65% upside21.57% upside41.69% upside41.69% upside

China Biologic Products (NASDAQ:CBPO) Consensus Price Target History

Price Target History for China Biologic Products (NASDAQ:CBPO)

China Biologic Products (NASDAQ:CBPO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018Jefferies GroupDowngradeBuy ➝ HoldLowView Rating Details
3/2/2018Deutsche BankSet Price TargetBuy$105.00HighView Rating Details
5/30/2017Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralMediumView Rating Details
3/3/2017Morgan StanleyReiterated RatingOverweight$135.00N/AView Rating Details
7/5/2016Credit Suisse GroupUpgradeNeutral ➝ OutperformN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

China Biologic Products (NASDAQ:CBPO) Earnings History and Estimates Chart

Earnings by Quarter for China Biologic Products (NASDAQ:CBPO)

China Biologic Products (NASDAQ:CBPO) Earnings Estimates

Current Year EPS Consensus Estimate: $4.71 EPS
Next Year EPS Consensus Estimate: $5.55 EPS

China Biologic Products (NASDAQ CBPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018$1.19N/AView Earnings Details
5/4/20183/31/2018$1.22$1.21$118.25 million$112.50 millionViewN/AView Earnings Details
2/28/2018Q4 17$0.89$0.90$85.15 million$90.10 millionViewN/AView Earnings Details
11/1/2017Q3 2017$1.30$1.11$99.56 millionViewN/AView Earnings Details
8/2/20176/30/2017$1.30$1.35$97.33 million$89.28 millionViewListenView Earnings Details
5/3/2017Q1 2017$1.24$1.32$91.45 millionViewN/AView Earnings Details
2/23/2017Q416$0.84$0.95$76.61 million$77.60 millionViewN/AView Earnings Details
11/2/2016Q316$1.05$1.22$88.46 million$86.50 millionViewN/AView Earnings Details
8/4/2016Q216$1.16$1.10$87.60 million$91.40 millionViewN/AView Earnings Details
5/4/2016Q116$0.88$0.94$74.00 million$85.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.55$0.74$66.77 million$68.30 millionViewListenView Earnings Details
11/3/2015Q315$0.81$0.82$75.30 million$78.80 millionViewN/AView Earnings Details
8/5/2015Q215$0.87$0.99$71.75 million$79.10 millionViewN/AView Earnings Details
5/6/2015Q1 15$0.84$0.87$70.35 millionViewN/AView Earnings Details
3/4/2015Q4 2014$0.48$58.00 millionViewN/AView Earnings Details
11/5/2014Q4 14$0.43$0.48$63.00 million$68.92 millionViewN/AView Earnings Details
8/5/2014Q2 2014$0.79$56.00 million$60.07 millionViewN/AView Earnings Details
5/6/2014Q1 2014$0.70$56.27 millionViewN/AView Earnings Details
3/12/2014Q413$0.38$0.35$41.50 million$42.60 millionViewN/AView Earnings Details
11/5/2013Q313$0.42$0.56$47.20 million$53.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.58$53.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.53$54.03 millionViewN/AView Earnings Details
3/13/2013Q4 2012$0.21ViewN/AView Earnings Details
11/8/2012Q312$0.54$41.30 million$53.10 millionViewN/AView Earnings Details
8/9/2012Q2 2012$0.46ViewN/AView Earnings Details
5/8/2012Q1 2012$0.39ViewN/AView Earnings Details
3/12/2012Q4 2011$0.28ViewN/AView Earnings Details
11/7/2011Q3 2011$0.42ViewN/AView Earnings Details
8/9/2011Q2 2011($0.06)ViewN/AView Earnings Details
5/9/2011Q1 2011$0.26$0.25ViewN/AView Earnings Details
3/31/2011Q4 2010$0.39$0.43ViewN/AView Earnings Details
11/16/2010Q3 2010$0.32$0.39ViewN/AView Earnings Details
8/16/2010Q2 2010$0.44$0.40ViewN/AView Earnings Details
5/17/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
3/23/2010Q4 2009$0.23$0.45ViewN/AView Earnings Details
11/16/2009Q3 2009$0.33ViewN/AView Earnings Details
8/17/2009Q2 2009$0.38ViewN/AView Earnings Details
5/18/2009Q1 2009$0.20ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

China Biologic Products (NASDAQ:CBPO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

China Biologic Products (NASDAQ CBPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.73%
Institutional Ownership Percentage: 54.58%
Insider Trading History for China Biologic Products (NASDAQ:CBPO)
Insider Trading History for China Biologic Products (NASDAQ:CBPO)

China Biologic Products (NASDAQ CBPO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2017Zhijing Cbpo LiuInsiderSell7,500$116.49$873,675.0010,969View SEC Filing  
3/2/2017Sean ShaoDirectorSell20,000$100.78$2,015,600.0036,000View SEC Filing  
3/1/2017David GaoCEOSell116,653$100.63$11,738,791.39449,396View SEC Filing  
8/15/2016Ming YangCFOSell21,092$124.32$2,622,157.4424,782View SEC Filing  
8/15/2016Wenfang LiuDirectorSell2,900$124.32$360,528.003,383View SEC Filing  
8/15/2016Zhijing Cbpo LiuInsiderSell1,968$124.32$244,661.76View SEC Filing  
6/8/2016Wp X Biologics LlcDirectorSell2,775,000$111.00$308,025,000.00View SEC Filing  
5/20/2016Ming YangCFOSell13,908$113.64$1,580,505.1252,282View SEC Filing  
5/20/2016Ming YinVPSell19,618$113.64$2,229,389.5251,419View SEC Filing  
3/11/2016Zhijing Cbpo LiuVPSell282$108.00$30,456.00718View SEC Filing  
3/7/2016Wp X Biologics LlcDirectorSell4,257,000$107.00$455,499,000.00View SEC Filing  
12/7/2015Zhijun TongDirectorSell15,000$118.33$1,774,950.0014,000View SEC Filing  
11/4/2015David GaoCEOSell95,991$115.60$11,096,559.60377,000View SEC Filing  
11/2/2015David GaoCEOSell12,891$112.26$1,447,143.66472,991View SEC Filing  
10/29/2015David GaoCEOSell71,118$110.21$7,837,914.78485,882View SEC Filing  
10/26/2015David GaoCEOSell59,542$105.22$6,265,009.24557,000View SEC Filing  
10/20/2015David GaoCEOSell258$105.00$27,090.00616,542View SEC Filing  
10/19/2015David GaoCEOSell200$105.03$21,006.00616,542View SEC Filing  
9/15/2015Ming YangCFOSell9,000$94.56$851,040.0024,782View SEC Filing  
9/15/2015Ming YinVPSell20,508$95.55$1,959,539.4013,467View SEC Filing  
9/14/2015Ming YangCFOSell11,304$97.08$1,097,392.3224,782View SEC Filing  
9/14/2015Wenfang LiuDirectorSell2,717$97.02$263,603.343,283View SEC Filing  
9/14/2015Zhijing Cbpo LiuVPSell6,786$99.29$673,781.94View SEC Filing  
6/15/2015Wp X Biologics LlcDirectorSell2,645,000$100.28$265,240,600.00View SEC Filing  
11/21/2014Zhijing Cbpo LiuVPSell8,000$68.95$551,600.00View SEC Filing  
11/10/2014Sean ShaoDirectorSell72,500$62.75$4,549,375.00View SEC Filing  
11/10/2014Zhijing Cbpo LiuVPSell7,500$62.75$470,625.00View SEC Filing  
9/15/2014Gang Cbpo YangVPSell2,454$54.00$132,516.00View SEC Filing  
9/15/2014Ming YangCFOSell6,164$54.00$332,856.00View SEC Filing  
9/12/2014Ming YinVPSell3,073$54.00$165,942.00View SEC Filing  
9/12/2013Wenfang LiuDirectorSell2,524$25.00$63,100.00View SEC Filing  
5/14/2013Wp X Biologics LlcDirectorBuy3,112,920$20.00$62,258,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

China Biologic Products (NASDAQ CBPO) News Headlines

Source:
DateHeadline
China Biologic Products (CBPO) Stock Rating Lowered by ValuEngineChina Biologic Products (CBPO) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 16 at 3:55 PM
China Biologic Products (CBPO) Given Average Recommendation of "Hold" by AnalystsChina Biologic Products (CBPO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 16 at 3:28 AM
$1.35 Earnings Per Share Expected for China Biologic Products (CBPO) This Quarter$1.35 Earnings Per Share Expected for China Biologic Products (CBPO) This Quarter
www.americanbankingnews.com - May 15 at 7:14 PM
China Biologic Products (CBPO) Upgraded to "Hold" at Zacks Investment ResearchChina Biologic Products (CBPO) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 7:04 PM
China Biologic Products (CBPO) Receives Hold Rating from Jefferies GroupChina Biologic Products (CBPO) Receives Hold Rating from Jefferies Group
www.americanbankingnews.com - May 14 at 11:40 AM
UPDATE: Jefferies Downgrades China Biologic Products (CBPO) to Hold Citing Lack of Visibility on the HorizonUPDATE: Jefferies Downgrades China Biologic Products (CBPO) to Hold Citing Lack of Visibility on the Horizon
www.streetinsider.com - May 14 at 9:35 AM
China Biologic Products (CBPO) Cut to Sell at BidaskClubChina Biologic Products (CBPO) Cut to Sell at BidaskClub
www.americanbankingnews.com - May 11 at 9:13 PM
Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead CandidateBlog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate
finance.yahoo.com - May 8 at 9:00 AM
China Biologic Products (CBPO) CEO David Gao on Q1 2018 Results - Earnings Call TranscriptChina Biologic Products' (CBPO) CEO David Gao on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 4:59 PM
China Biologic Products (CBPO) Announces  Earnings ResultsChina Biologic Products (CBPO) Announces Earnings Results
www.americanbankingnews.com - May 5 at 1:40 PM
China Biologic Q1 sales up 23%; earnings up 5%; cash flow up 79%China Biologic Q1 sales up 23%; earnings up 5%; cash flow up 79%
seekingalpha.com - May 5 at 9:17 AM
After-Hours Earnings Report for May 4, 2018 : BWXT, CBPOAfter-Hours Earnings Report for May 4, 2018 : BWXT, CBPO
www.nasdaq.com - May 4 at 4:47 PM
BRIEF-China Biologic Q1 Earnings Per Share $0.92BRIEF-China Biologic Q1 Earnings Per Share $0.92
www.reuters.com - May 4 at 4:47 PM
China Biologic Products: 1Q Earnings SnapshotChina Biologic Products: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 4:47 PM
China Biologic Reports Financial Results for the First Quarter of 2018China Biologic Reports Financial Results for the First Quarter of 2018
finance.yahoo.com - May 4 at 4:47 PM
Is There An Opportunity With China Biologic Products Holdings Inc’s (NASDAQ:CBPO) 39% Undervaluation?Is There An Opportunity With China Biologic Products Holdings Inc’s (NASDAQ:CBPO) 39% Undervaluation?
finance.yahoo.com - April 30 at 4:44 PM
Guillain-Barré Syndrome Market to reach value of US$ 708.6 Mn by 2025, Says TMRGuillain-Barré Syndrome Market to reach value of US$ 708.6 Mn by 2025, Says TMR
globenewswire.com - April 30 at 9:10 AM
$1.28 EPS Expected for China Biologic Products (CBPO) This Quarter$1.28 EPS Expected for China Biologic Products (CBPO) This Quarter
www.americanbankingnews.com - April 28 at 5:14 AM
Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Got Enough Cash?Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Got Enough Cash?
finance.yahoo.com - April 27 at 4:46 PM
China Biologic Products (CBPO) Scheduled to Post Earnings on MondayChina Biologic Products (CBPO) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 24 at 8:10 PM
China Biologic Products (CBPO) Rating Lowered to Sell at ValuEngineChina Biologic Products (CBPO) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 21 at 8:42 AM
China Biologic Products (CBPO) Receives Average Rating of "Hold" from AnalystsChina Biologic Products (CBPO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 21 at 3:30 AM
China Biologic Products (CBPO) Lowered to "Sell" at BidaskClubChina Biologic Products (CBPO) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 18 at 12:16 PM
 Analysts Anticipate China Biologic Products (CBPO) Will Announce Earnings of $1.28 Per Share Analysts Anticipate China Biologic Products (CBPO) Will Announce Earnings of $1.28 Per Share
www.americanbankingnews.com - April 11 at 8:43 AM
BidaskClub Upgrades China Biologic Products (CBPO) to "Hold"BidaskClub Upgrades China Biologic Products (CBPO) to "Hold"
www.americanbankingnews.com - April 7 at 7:02 AM
China Biologic Products Holdings, Inc. (CBPO) Receives Average Recommendation of "Hold" from BrokeragesChina Biologic Products Holdings, Inc. (CBPO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 27 at 3:26 AM
$1.28 EPS Expected for China Biologic Products Holdings, Inc. (CBPO) This Quarter$1.28 EPS Expected for China Biologic Products Holdings, Inc. (CBPO) This Quarter
www.americanbankingnews.com - March 25 at 8:48 AM
China Biologic Products (CBPO) Upgraded to "Sell" by BidaskClubChina Biologic Products (CBPO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM
China Biologic Products (CBPO) and Galmed Pharmaceuticals (GLMD) Head to Head ContrastChina Biologic Products (CBPO) and Galmed Pharmaceuticals (GLMD) Head to Head Contrast
www.americanbankingnews.com - March 16 at 3:13 AM
China Biologic Products (CBPO) "Buy" Rating Reiterated at Jefferies GroupChina Biologic Products' (CBPO) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - March 15 at 12:26 PM
China Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.28 Per ShareChina Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.28 Per Share
www.americanbankingnews.com - March 8 at 1:08 AM
China Biologic Products Holdings, Inc. (CBPO) Position Lifted by Bank of New York Mellon CorpChina Biologic Products Holdings, Inc. (CBPO) Position Lifted by Bank of New York Mellon Corp
www.americanbankingnews.com - March 6 at 4:54 AM
China Biologic Products (CBPO) Downgraded by Zacks Investment ResearchChina Biologic Products (CBPO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 5 at 7:20 PM
China Biologic Products (CBPO) PT Set at $105.00 by Deutsche BankChina Biologic Products (CBPO) PT Set at $105.00 by Deutsche Bank
www.americanbankingnews.com - March 3 at 6:12 PM
China Biologic Products (CBPO) Lowered to Strong Sell at BidaskClubChina Biologic Products (CBPO) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM
China Biologic Products (CBPO) Downgraded by TheStreetChina Biologic Products (CBPO) Downgraded by TheStreet
www.americanbankingnews.com - March 3 at 1:56 PM
China Biologic Products Holdings, Inc. (CBPO) Given Consensus Rating of "Hold" by BrokeragesChina Biologic Products Holdings, Inc. (CBPO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 2 at 4:30 PM
China Biologic Products (CBPO) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSChina Biologic Products (CBPO) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - February 28 at 9:20 PM
Comerica Bank Sells 4,290 Shares of China Biologic Products Holdings, Inc. (CBPO)Comerica Bank Sells 4,290 Shares of China Biologic Products Holdings, Inc. (CBPO)
www.americanbankingnews.com - February 27 at 7:14 AM
Analysts Anticipate China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 EPSAnalysts Anticipate China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 EPS
www.americanbankingnews.com - February 27 at 1:36 AM
China Biologic Products Holdings, Inc. (CBPO) Shares Sold by Schroder Investment Management GroupChina Biologic Products Holdings, Inc. (CBPO) Shares Sold by Schroder Investment Management Group
www.americanbankingnews.com - February 26 at 1:50 PM
China Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial ResultsChina Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial Results
finance.yahoo.com - February 23 at 9:01 AM
China Biologic Products (CBPO) Upgraded at BidaskClubChina Biologic Products (CBPO) Upgraded at BidaskClub
www.americanbankingnews.com - February 19 at 3:38 PM
 Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 Earnings Per Share Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Announce $1.11 Earnings Per Share
www.americanbankingnews.com - February 19 at 12:16 PM
China Biologic to Build New Collection Station in Hainan ProvinceChina Biologic to Build New Collection Station in Hainan Province
finance.yahoo.com - February 14 at 9:26 AM
Zacks: Analysts Set $111.67 Target Price for China Biologic Products Holdings, Inc. (CBPO)Zacks: Analysts Set $111.67 Target Price for China Biologic Products Holdings, Inc. (CBPO)
www.americanbankingnews.com - February 12 at 1:34 AM
Should You Expect China Biologic Products Holdings Inc (NASDAQ:CBPO) To Continue Delivering An ROE Of 20.70%?Should You Expect China Biologic Products Holdings Inc (NASDAQ:CBPO) To Continue Delivering An ROE Of 20.70%?
finance.yahoo.com - February 9 at 4:44 PM
China Biologic Products (CBPO) Rating Increased to Hold at Zacks Investment ResearchChina Biologic Products (CBPO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 5 at 7:40 PM
China Biologic Products (CBPO) Downgraded to "Strong Sell" at BidaskClubChina Biologic Products (CBPO) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
China Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.11 Per ShareChina Biologic Products Holdings, Inc. (CBPO) Expected to Post Earnings of $1.11 Per Share
www.americanbankingnews.com - February 2 at 2:22 PM

SEC Filings

China Biologic Products (NASDAQ:CBPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

China Biologic Products (NASDAQ:CBPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

China Biologic Products (NASDAQ CBPO) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.